Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Recruiting now · Phase 2
Conditions studied: Prostate Cancer
In brief
The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.
Key facts
- Study ID
- NCT07163910
- Run by
- baotai Liang
- People needed
- 93
- Starts
- 2025-04-20
- Expected to finish
- 2027-12-20
- Last updated by the study team
- 2025-11-18
Who can join
Age: 18 and older, up to 85. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Zhongda Hospital — Nanjing, Jiangsu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.